These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36471601)

  • 1. [Serum troponin-I as a marker of fibroblast growth factor-23 (FGF-23) cardiotoxic effect, in patients with chronic kidney disease].
    Taranova MV; Milovanova LY; Kozlovskaya Lysenko LV; Milovanova SY; Androsova TV; Zubacheva DO; Lebedeva MV; Dobrosmyslov IA; Kozlov VV; Kuchieva AM; Li OA; Reshetnikov VA
    Ter Arkh; 2019 Jun; 91(6):85-92. PubMed ID: 36471601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular remodeling as a result of fibroblast growth factor-23 (FGF-23)/Klotho imbalance in patients with CKD.
    Milovanova LY; Taranova MV; Milovanova SY; Kozlovskaya Lysenko LV; Pasechnik AI; Kozlov VV; Beketov VD; Volkov AV; Ratanov M
    Int Urol Nephrol; 2022 Jul; 54(7):1613-1621. PubMed ID: 34718928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Low protein diet with essential amino acids ketoanalogues combination can affect serum FGF-23 and Klotho levels in chronic kidney disease 3b-4 stages patients: randomized pilot study].
    Milovanova LY; Kozlovskaya Lysenko LV; Androsova TV; Lebedeva MV; Taranova MV; Milovanova SY; Kondratyeva TB; Zubacheva DO; Tchebotareva NV; Kozlov VV; Kuchieva AM; Li OA; Reshetnikov VA
    Ter Arkh; 2019 Jun; 91(6):47-56. PubMed ID: 36471595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration.
    Milovanova LY; Dobrosmyslov IA; Milovanov YS; Taranova MV; Kozlov VV; Milovanova SY; Kozevnikova EI
    Ter Arkh; 2018 Jun; 90(6):48-54. PubMed ID: 30701904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New markers of cardio-renal links in chronic kidney disease].
    Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
    Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
    Milovanova LY; Kozlovskaya LV; Markina MM; Milovanova SY; Borisov AA; Mukhin NA; Fomin VV; Moiseev SV
    Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD.
    Smith K; deFilippi C; Isakova T; Gutiérrez OM; Laliberte K; Seliger S; Kelley W; Duh SH; Hise M; Christenson R; Wolf M; Januzzi J
    Am J Kidney Dis; 2013 Jan; 61(1):67-73. PubMed ID: 22883134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b-4 stages chronic кidney disease patients: a randomized pilot study.
    Milovanova L; Fomin V; Moiseev S; Taranova M; Milovanov Y; Lysenko Kozlovskaya L; Kozlov V; Kozevnikova E; Milovanova S; Lebedeva M; Reshetnikov V
    Clin Exp Nephrol; 2018 Dec; 22(6):1351-1359. PubMed ID: 29948444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Low serum Klotho level as a predictor of calcification of the heart and blood vessels in patients with CKD stages 2-5D].
    Milovanova LY; Lysenko Kozlovskaya LV; Milovanova SY; Taranova MV; Kozlov VV; Reshetnikov VA; Lebedeva MV; Androsova TV; Zubacheva DO; Chebotareva NV
    Ter Arkh; 2020 Jul; 92(6):37-45. PubMed ID: 33346491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of the morphogenetic proteins FGF-23 and Klotho as predictors of prognosis of chronic kidney disease].
    Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
    Ter Arkh; 2014; 86(4):36-44. PubMed ID: 24864466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in FGF-23, Neutrophil/Platelet Activation Markers, and Angiogenin in Advanced Chronic Kidney Disease and Their Effect on Arterial Stiffness.
    Choi HM; Kwon YE; Kim S; Oh DJ
    Kidney Blood Press Res; 2019; 44(5):1166-1178. PubMed ID: 31553973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Decreased Serum Levels of Klotho Protein in Chronic Kidney Disease Patients: Clinical Imortance].
    Milovanova LY; Mukhin NA; Kozlovskaya LV; Milovanov YS; Kiyakbaev GG; Rogova IV; Lebedeva MV; Androsova TV; Milovanova SY; Gil AY; Taranova MV
    Vestn Ross Akad Med Nauk; 2016; 71(4):288-96. PubMed ID: 29297646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of fibroblast growth factor 23 in the development of cardiovascular diseases in patients with end-stage renal failure on programmed hemodialysis].
    Dzgoeva FU; Sopoev MY; Bestaeva TL; Khamitsaeva OV; Ktsoeva FA; Sageeva RO
    Ter Arkh; 2016; 88(12):51-56. PubMed ID: 28139560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart.
    Ford ML; Smith ER; Tomlinson LA; Chatterjee PK; Rajkumar C; Holt SG
    Nephrol Dial Transplant; 2012 Feb; 27(2):727-33. PubMed ID: 21750158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.
    Lim K; Lu TS; Molostvov G; Lee C; Lam FT; Zehnder D; Hsiao LL
    Circulation; 2012 May; 125(18):2243-55. PubMed ID: 22492635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study.
    Kim HJ; Kang E; Oh YK; Kim YH; Han SH; Yoo TH; Chae DW; Lee J; Ahn C; Oh KH
    BMC Nephrol; 2018 Mar; 19(1):51. PubMed ID: 29506503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
    Lioufas NM; Pedagogos E; Hawley CM; Pascoe EM; Elder GJ; Badve SV; Valks A; Toussaint ND;
    Am J Nephrol; 2020; 51(3):201-215. PubMed ID: 32023606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease.
    Di Lullo L; Gorini A; Bellasi A; Morrone LF; Rivera R; Russo L; Santoboni A; Russo D
    Clin Kidney J; 2015 Dec; 8(6):732-6. PubMed ID: 26613033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.